Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment
Aims:
To prepare lamivudine (LAM)-loaded-nanoparticles (NPs) that can be used in lung cancer treatment. To change the antiviral indication of LAM to anticancer.
Background:
The development of anticancer drugs is a difficult process. One approach to accelerate the availability of drugs is to reclassify drugs approved for other conditions as anticancer. The most common route of administration of anticancer drugs is intravenous injection. Oral administration of anticancer drugs may considerably change current treatment modalities of chemotherapy and improve the life quality of cancer patients. There is also a potentially significant economic advantage.
Objective:
To characterize the LAM-loaded-NPs and examine the anticancer activity.
Methods:
LAM-loaded-NPs were prepared using Nano Spray-Dryer. Properties of NPs were elucidated by particle size (PS), polydispersity index (PDI), zeta potential (ZP), SEM, encapsulation efficiency (EE%), dissolution, release kinetics, DSC and FT-IR. Then, the anticancer activity of all NPs was examined.
Results:
The PS values of the LAM-loaded-NPs were between 373 and 486 nm. All NPs prepared have spherical structure and positive ZP. EE% was in a range of 61-79%. NPs showed prolonged release and the release kinetics fitted to the Weibull model. NPs structures were clarified by DSC and FT-IR analysis. The results showed that the properties of NPs were directly related to the drug:polymer ratio of feed solution. NPs have potential anticancer properties against A549 cell line at low concentrations and non-toxic to CCD 19-Lu cell line.
Conclusion:
NPs have potential anticancer properties against human lung adenocarcinoma cells and may induce cell death effectively and be a potent modality to treat this type of cancer. These experiments also indicate that our formulations are non-toxic to normal cells. It is clear that this study would bring a new perspective to cancer therapy.
Top-30
Citations by journals
1
2
|
|
Assay and Drug Development Technologies
2 publications, 14.29%
|
|
Pharmaceutics
2 publications, 14.29%
|
|
Microvascular Research
1 publication, 7.14%
|
|
Asian Journal of Pharmaceutical Sciences
1 publication, 7.14%
|
|
Journal of Drug Delivery Science and Technology
1 publication, 7.14%
|
|
Bioorganic Chemistry
1 publication, 7.14%
|
|
Journal of Heterocyclic Chemistry
1 publication, 7.14%
|
|
Journal of Cellular and Molecular Medicine
1 publication, 7.14%
|
|
Current Drug Delivery
1 publication, 7.14%
|
|
International Journal of Molecular Sciences
1 publication, 7.14%
|
|
ACS Omega
1 publication, 7.14%
|
|
Scientific Reports
1 publication, 7.14%
|
|
1
2
|
Citations by publishers
1
2
3
|
|
Elsevier
3 publications, 21.43%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
3 publications, 21.43%
|
|
Mary Ann Liebert
2 publications, 14.29%
|
|
Wiley
2 publications, 14.29%
|
|
Shenyang Pharmaceutical University
1 publication, 7.14%
|
|
Bentham Science
1 publication, 7.14%
|
|
American Chemical Society (ACS)
1 publication, 7.14%
|
|
Springer Nature
1 publication, 7.14%
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.